Peer-reviewed veterinary case report
Gene expression linked to remission in dogs with lymphoma on CHOP
By Miles W. Mee et al.·Published in BMC Research Notes·2022·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma, the most common blood cancer in dogs, were treated with a standard chemotherapy called CHOP, which includes several medications. While about 70-85% of dogs respond well and go into remission, many eventually relapse. Researchers studied the gene expression in these dogs before starting treatment to find potential markers that could predict which dogs might not achieve long-lasting remission. The findings could help improve treatment strategies for dogs with lymphoma in the future.
People also search for: dog lymphoma treatment · CHOP chemotherapy for dogs · canine cancer remission duration
Abstract
Objectives Canine lymphoma, the most common hematological cancer in dogs, shares many molecular and clinical characteristics with human Non-Hodgkin lymphoma (NHL). The standard treatment for canine lymphoma is “CHOP” multiagent chemotherapy protocol consisting of Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Vincristine (Oncovin™), and Prednisone. Approximately 70–85% of patients treated with CHOP achieve clinical remission. However, duration of remission varies and the majority of dogs eventually relapse. To identify possible biomarkers for patients failing to achieve remission, we performed RNA-Seq analysis on 25 cases of canine lymphoma obtained prior the start of their CHOP therapy regime and assessed gene expression associated with patient progression free survival (PFS). Data description The data consists of (1) raw RNA-Seq reads in 75 bp fastq format from fine needle aspirate samples of enlarged lymph nodes from canine patients with naturally occurring lymphoma; (2) Fragments Per Kilobase Million (FPKM) values for each sample; (3) raw transcript counts for each sample; (4) anonymized patient details including PFS; (5) heat map of gene expression and (6) Cox proportional hazard analysis showing significantly expressed genes. These data may be useful for comparative analysis of gene expression in human NHL and analysis of gene expression associated with disease outcome in canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/35317846